标准生物工具公司2025年季度报告

FORM10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934For the quarterly period endedMarch 31,2025 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934For the transition period from STANDARD BIOTOOLS INC. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 duringthe preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for thepast 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” inRule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 1, 2025, there were379,822,268shares of the registrant’s common stock, $0.001 par value per share, outstanding. Special Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Actof 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “ExchangeAct”), that are based on our management’s beliefs and assumptions and on information currently available to our management. Theforward-looking statements are contained principally in the section titled “Management’s Discussion and Analysis of FinancialCondition and Results of Operations.” Forward-looking statements include information concerning our possible or assumed futurecash flow, revenue, sources of revenue and results of operations, cost of product revenue and product margin, operating and otherexpenses, unit sales and the selling prices of our products, timing of shipments, business strategies, financing plans, expansion ofour business, investments to expand our customer base, plans for our products, competitive position, industry environment,anticipated National Institutes of Health funding pressures, the expected effect from U.S. export controls and tariffs, potential Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results,performance, or achievements to be materially different from any future results, performance, or achievements expressed orimplied by the forward-looking statements. We discuss these risks in greater detail in the “Risk Factors” section our Annual Reporton Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (the “SEC”) on March Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this Quarterly Report onForm 10-Q. Except as required by law, we assume no obligation to update these forward-looking statements, or to update thereasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information Standard BioTools, the Standard BioTools logo, Fluidigm®, the Fluidigm logo, 48.Atlas™, Access Array™, Advanta™, AdvantaEASE™, Atlas™, Biomark™, “Bringing new insights to life”™, C1™, Callisto™, Cell-ID™, CyTOF®, CyTOF XT™, theCyTOF XT logo, D3™, Delta Gene™, Direct™, Digital Array™, Dynamic Array™, EP1™, EQ™, FC1™, Flex Six™, FlowConductor™, FluiDesign™, Helios™, High-Precision 96.96 Genotyping™, HTI™, Hyperion™, Hyperion+™, IMC™, ImagingMass Cytometry™, Immune Profiling Assay™, Juno™, Maxpar®, MCD™, MSL®, Nanoflex™, Open App™, Pathsetter™,Polaris™, qdPCR 37K™, Script Builder™, Script Hub™, Singular™, SNP Trace™, SNP Type™, “Unleashing tools to acceleratebreakthroughs in human health”™, X9™ Real Time PCR System, Xgrade™, SomaLogic®, SomaScan®, SOMAmer®,SomaSignal®, Power by SomaLogic™, DataDelve™, KREX™, Sengenics™, i-Ome™, OncoREX™, and CardioDM™ are trademarks or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. Otherservice marks, trademarks and trade names referred to in this Quarterly Report on Form 10-Q are the property of their respect